List of Bylvay drug patents

Bylvay is owned by Albireo.

Bylvay contains Odevixibat.

Bylvay has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Bylvay are:

  • US7132416

Bylvay was authorised for market use on 20 July, 2021.

Bylvay is available in capsule, pellets;oral, capsule;oral dosage forms.

Bylvay can be used as method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic), method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic).

Drug patent challenges can be filed against Bylvay from 2025-07-20.

The generics of Bylvay are possible to be released after 12 November, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416 ALBIREO Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
Sep, 2022

(8 months ago)

US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10487111 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10981952 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US9694018 ALBIREO IBAT inhibitors for the treatment of liver disease
Nov, 2031

(8 years from now)

US10011633 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US10093697 ALBIREO IBAT inhibitors for the treatment of liver diseases
Nov, 2031

(8 years from now)

US11365182 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

US11583539 ALBIREO Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors
Nov, 2041

(18 years from now)

Do you want to check out BYLVAY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

BYLVAY family patents

20

United States

7

European Union

6

Sweden

5

China

5

Japan

5

Hungary

4

Spain

4

Denmark

4

Poland

4

Brazil

4

Canada

4

Korea, Republic of

4

Israel

4

Portugal

4

Slovenia

4

Australia

4

Lithuania

3

Hong Kong

3

RS

3

United Kingdom

3

Singapore

3

Croatia

3

Mexico

3

Colombia

2

Philippines

2

Malaysia

2

Russia

2

Norway

2

Nicaragua

2

Cyprus

2

Peru

2

Chile

2

Taiwan

2

Jordan

2

Costa Rica

2

Ecuador

2

South Africa

1

Uruguay

1

Austria

1

Turkey

1

Iceland

1

Germany

1

Ukraine

1

Argentina

1

ME

1

New Zealand

1

San Marino

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in